Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
mediaposted on 2022-03-21, 09:08 authored by Adis journals on behalf of, Bob Geng, Adelaide A. Hebert, Liza Takiya, Lauren Miller, John L. Werth, Chuanbo Zang, Paul Sanders, Mark G. Lebwohl
Article full text
The above video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022.